19 hours Ago By ABMN Staff
Penumbra ( NYSE:PEN – Get Free Report ) had its target price increased by equities researchers at JPMorgan Chase & Co. from $230.00 to $285.
00 in a research note issued on Wednesday, Benzinga reports. The firm presently has an “overweight” rating on the stock. JPMorgan Chase & Co.
‘s target price indicates a potential downside of 5.88% from the company’s previous close. A number of other research analysts have also weighed in on the company.
UBS Group raised their price objective on Penumbra from $305.00 to $320.00 and gave the company a “buy” rating in a research report on Wednesday.
Wells Fargo & Company boosted their target price on shares of Penumbra from $275.00 to $305.00 and gave the company an “overweight” rating in a research report on Wednesday.
Canaccord Genuity Group raised their price objective on Penumbra from $323.00 to $340.00 and gave the stock a “buy” rating in a research note on Wednesday.
Piper Sandler restated an “overweight” rating and set a $330.00 target price (up previously from $250.00) on shares of Penumbra in a research note on Wednesday.
Finally, Oppenheimer initiated coverage on shares of Penumbra in a research report on Tuesday, December 17th. They issued an “outperform” rating and a $275.00 price target for the company.
Three research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $292.64.
Check Out Our Latest Research Report on Penumbra Penumbra Trading Down 0.3 % Penumbra ( NYSE:PEN – Get Free Report ) last announced its quarterly earnings data on Tuesday, February 18th. The company reported $0.
97 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.09.
The firm had revenue of $315.52 million for the quarter, compared to analysts’ expectations of $311.63 million.
Penumbra had a return on equity of 9.73% and a net margin of 1.17%.
Equities research analysts forecast that Penumbra will post 3.86 earnings per share for the current fiscal year. Insider Buying and Selling at Penumbra In related news, Director Harpreet Grewal sold 167 shares of the stock in a transaction on Friday, January 3rd.
The stock was sold at an average price of $241.28, for a total transaction of $40,293.76.
Following the sale, the director now owns 8,530 shares in the company, valued at approximately $2,058,118.40. This represents a 1.
92 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink . Also, CAO Lambert Shiu sold 1,798 shares of the firm’s stock in a transaction dated Friday, November 29th.
The stock was sold at an average price of $242.56, for a total transaction of $436,122.88.
Following the completion of the sale, the chief accounting officer now owns 20,682 shares of the company’s stock, valued at $5,016,625.92. This trade represents a 8.
00 % decrease in their position. The disclosure for this sale can be found here . Insiders sold 18,219 shares of company stock worth $4,426,439 in the last quarter.
5.00% of the stock is owned by corporate insiders. Institutional Trading of Penumbra Large investors have recently made changes to their positions in the stock.
FMR LLC raised its stake in shares of Penumbra by 2.1% during the third quarter. FMR LLC now owns 5,896,396 shares of the company’s stock valued at $1,145,729,000 after acquiring an additional 121,465 shares in the last quarter.
Champlain Investment Partners LLC lifted its holdings in Penumbra by 20.6% during the third quarter. Champlain Investment Partners LLC now owns 1,547,972 shares of the company’s stock worth $300,786,000 after buying an additional 264,122 shares during the period.
State Street Corp lifted its holdings in Penumbra by 0.3% during the third quarter. State Street Corp now owns 1,236,671 shares of the company’s stock worth $240,298,000 after buying an additional 3,863 shares during the period.
RTW Investments LP boosted its position in Penumbra by 8.4% during the 4th quarter. RTW Investments LP now owns 862,450 shares of the company’s stock valued at $204,815,000 after acquiring an additional 66,700 shares in the last quarter.
Finally, Baillie Gifford & Co. increased its holdings in shares of Penumbra by 23.4% in the 4th quarter.
Baillie Gifford & Co. now owns 730,233 shares of the company’s stock valued at $173,416,000 after acquiring an additional 138,387 shares during the period. 88.
88% of the stock is owned by hedge funds and other institutional investors. About Penumbra ( Get Free Report ) Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.
Featured Articles Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter ..
